Press

What is CHINATRIALS17?

CHINATRIALS is an annual summit connecting global pharmaceutical/biotech development professionals, primarily in China and the Asia-Pacific region. It
serves as an international clinical development forum, attracting not only pharmaceutical companies and biotech ventures from China and mainland China, but also biotech companies, pharmaceutical companies, CROs (contract clinical development organizations), medical institutions, and investors from Europe, the United States, and other Asian countries.
Its purpose is to serve as a platform for accelerating clinical development, business development (BD), licensing agreements, fundraising, and the search for new partners in Asia, particularly promoting cross-border collaboration between China, Asia, and the West.
chinatrials.com

Dates: November 12-14, 2025
Venue: JW Marriott Hotel Shanghai at Tomorrow Square, Shanghai, China.
Participation size: Officially targeted at approximately 500 participants, many of whom are director-level or above from global pharmaceutical, biotech, CRO, and medical institutions.
Program contents: Keynote speeches and panel discussions on the latest trends in drug discovery and clinical development, the role and opportunities of the Asian and Chinese markets, sessions on clinical trial design, operations, and development strategies for oncology, rare diseases, and new modalities (cell/gene therapy, etc.), and a Business Development/Investor Track for licensing, business development, and investment.
Booths from CROs, CDMOs, medical institutions, and development support vendors were also exhibiting—a networking and partner matching opportunity.

COO Aoyagi commented: “
I was truly impressed by how rapidly China’s clinical trial market is expanding.
Not only are we seeing the number of trials increasing, but we’re also seeing significant growth in the IT vendors supporting the ecosystem.
While it’s still difficult to find local vendors that offer true one-stop solutions in Japan, the situation in China is very different.
I was amazed by the level of commitment and scale of investment these companies are putting into system development, and I learned a lot.”
As Buzzreach continues to build a DCT framework in Japan, we are deeply impressed by the capabilities and vision of Xincere ( https://en.xinceremed.com/ ) and Taimei Technology ( https://www.taimei.com/en/
). In Japan, more than 70% of drugs approved overseas remain unapproved domestically.
This “drug lag loss” remains a major challenge.
As a technology vendor specializing in patient recruitment and clinical trials, Buzzreach is committed to addressing this challenge by reducing the burden on patients and building a DCT environment that enables research in Japan to be conducted more efficiently. We look forward to continuing
to learn and collaborate across borders to accelerate access to innovative treatments.